Glucagen Hypokit

Glucagen Hypokit is a prescription‑only glucagon product marketed in the European Union. It contains the active ingredient glucagon in a ready‑to‑use kit designed for intramuscular, intravenous, or subcutaneous injection. The kit provides a rapid‑acting formulation that is used by healthcare professionals and trained caregivers to treat severe hypoglycemia when oral carbohydrate intake is not possible. The product comes in a single‑dose cartridge with a compatible needle and clear emergency‑use instructions.

Glucagen Hypokit is indicated for the rapid treatment of severe hypoglycemia in patients with diabetes when immediate glucose elevation is required.

- Emergency reversal of hypoglycemia when the patient is unconscious, unable to swallow, or experiencing seizures. - Use in adults and children with type 1 or type 2 diabetes who have taken excess insulin or oral hypoglycemic agents. - Administration by trained medical personnel, emergency responders, or caregivers in a non‑hospital setting. - Provides an alternative to oral glucose when intravenous dextrose is not readily available.

The pharmacologic action of glucagon can produce a range of transient effects, most of which are mild and self‑limiting.

Common: - Nausea or vomiting - Flushing or warmth at the injection site - Transient headache - Mild abdominal discomfort

Serious: - Severe allergic reaction (anaphylaxis) with rash, itching, swelling, or difficulty breathing - Rapid heart rate (tachycardia) or irregular heartbeat - Marked rise in blood pressure

Before using Glucagen Hypokit, certain safety considerations should be reviewed to minimize risks.

- Verify the patient’s diagnosis of severe hypoglycemia and confirm that oral glucose administration is not feasible. - Ensure proper reconstitution and correct injection technique according to the kit instructions. - Store the kit at controlled room temperature; discard after the expiration date or if the solution appears discolored. - Use with caution in patients with known glucagon allergy or a history of pheochromocytoma. - Monitor the patient’s blood glucose after administration and provide additional medical care if levels remain low.

Glucagon may interact with other medications, affecting its efficacy or safety profile.

Avoid: - Beta‑blockers, which can blunt the expected rise in blood glucose. - Long‑acting insulin analogues that may prolong hypoglycemia despite glucagon administration.

Use with caution: - Oral hypoglycemic agents (e.g., sulfonylureas) that may increase the risk of recurrent hypoglycemia after glucagon. - Catecholamine‑releasing drugs that could exacerbate cardiovascular effects such as tachycardia. - Anticholinergic medications that may interfere with gastrointestinal motility and affect glucagon absorption.